|
gptkb:Anavex_Life_Sciences_Corp.
|
ANAVEX2-73 Phase 2/3 for Rett syndrome
|
|
gptkb:IDO1_gene
|
gptkb:immunotherapy
|
|
gptkb:rebastinib
|
Phase 1/2
|
|
gptkb:beloranib
|
gptkb:Prader-Willi_syndrome
|
|
gptkb:Ebola_vaccine_(Ad26.ZEBOV)
|
conducted in Africa and Europe
|
|
gptkb:Calquence
|
gptkb:ASCEND
|
|
gptkb:troponin
|
troponin I test
|
|
gptkb:Acelarin
|
Phase III (as of 2023)
|
|
gptkb:SRF388
|
gptkb:NCT04374877
|
|
gptkb:rVSVΔG-ZEBOV-GP
|
gptkb:Ebola_ça_Suffit!
|
|
gptkb:TGFBR2_gene
|
genetic testing for Loeys-Dietz syndrome
|
|
gptkb:ONCR-177
|
NCT04348916
|
|
gptkb:Integra_Dermal_Regeneration_Template
|
demonstrated improved healing in burn patients
|
|
gptkb:Fractyl_Health
|
Revita-2
|
|
gptkb:COL11A1_gene
|
genetic testing for Stickler syndrome
|
|
gptkb:ERBB1
|
EGFR mutation analysis
|
|
gptkb:OncoSec_Medical
|
KEYNOTE-695
|
|
gptkb:verubecestat
|
Phase III (terminated)
|
|
gptkb:EORTC-NCIC_trial
|
NCT00006353
|
|
gptkb:saracatinib
|
NCT02167256
|